- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00164736
Breastfeeding, Antiretroviral, and Nutrition Study
HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health
This is a comparative clinical trial among HIV-infected women and their infants to determine:
- the benefit of nutritional supplementation given to women during breastfeeding
- the benefit and safety of antiretroviral (ARV) medications given either to infants or to their mothers to prevent HIV transmission during breastfeeding
- the feasibility of exclusive breastfeeding followed by early, rapid breastfeeding cessation
연구 개요
상태
정황
상세 설명
This study addresses the complex issues of HIV related maternal morbidity, mortality, and postnatal HIV transmission during breastfeeding and weaning in resource-poor countries. Objectives include assessment of mortality and morbidity among HIV-infected women; evaluation of interventions to reduce HIV transmission to infants exposed by breast milk; and assessment of early weaning as a risk-reduction strategy for infants of HIV-infected mothers.
The study will evaluate the following:
- The efficacy of a high-density caloric/micronutrient nutritional supplement given to HIV-infected women who breastfeed in preventing maternal depletion (weight loss and micronutrient status).
- The safety and efficacy of maternal or infant antiretroviral regimens, taken for up to 6 months during breastfeeding, in reducing infant HIV infection rates at 48 weeks.
- The feasibility of exclusive breastfeeding for 6 months followed by rapid weaning.
Additional study objectives are to evaluate the feasibility of delivering these interventions in resource poor settings and to identify maternal, infant, and virologic factors associated with HIV transmission during breastfeeding.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Lilongwe, 말라위
- Kamuzu Central Hospital, Bottom Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Recruitment and primary eligibility criteria:
- Age > 14 years.
- Ability to give informed assent or consent.
- Evidence of HIV infection, as documented by 2 positive ELISA antibody tests; or 1 positive ELISA, and 1 Western Blot; or 2 separate concurrent rapid tests.
- Currently pregnant (with a single or multiple fetuses).
- Gestation < 30 weeks at referral from 'Call to Action' Program
- No serious current complications of pregnancy.
- Intention to breastfeed.
- Intention to deliver at the institution at which the study is based.
- Not previously enrolled in this study for an earlier pregnancy.
- Other than HIV, no active serious infection, such as tuberculosis or other potentially serious illnesses.
- No previous use of antiretrovirals including the HIVNET 012 regimen.
- Mother's CD4 count > 250 cells/uL determined in the antenatal clinic.
- Mother's ALT < 2.5 x ULN (upper limit of normal) determined in the antenatal clinic
Secondary eligibility criteria and treatment assignment:
- Mother who delivers outside of the institution at which the study is based must present with her infant to the study site within 36 hours of delivery.
- Mother accepts nevirapine and zidovudine+lamivudine 7-day regimen for herself and her infant.
- Infant birth weight > 2000 g.
- No severe congenital malformations or other condition(s) not compatible with life.
- Based on clinical assessment, no maternal condition which would preclude the start of the study intervention.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: Maternal ARVs & Nutrition Supplement
Extended maternal ARVs for prophylaxis (for the infant) & daily nutritional supplement given to the mother
|
Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food).
Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day).
Commencing after delivery and through to 28 weeks.
다른 이름들:
High energy, nutrient-dense, micronutrient fortified nutritional supplement.
Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation.
Vitamin A is excluded.
다른 이름들:
|
활성 비교기: Infant NVP & Nutrition Supplement
Extended infant nevirapine for prophylaxis & daily nutritional supplment given to the mother
|
High energy, nutrient-dense, micronutrient fortified nutritional supplement.
Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation.
Vitamin A is excluded.
다른 이름들:
Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg. To 28 weeks while breastfeeding.
다른 이름들:
|
활성 비교기: Maternal ARVs & No Nutrition Supplement
Extended maternal ARVs for prophylaxis (for the infant) & no nutritional supplement given to the mother
|
Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food).
Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day).
Commencing after delivery and through to 28 weeks.
다른 이름들:
|
활성 비교기: Infant NVP & No Nutrition Supplement
Extended infant nevirapine for prophylaxis & no nutritional supplment given to the mother
|
Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg. To 28 weeks while breastfeeding.
다른 이름들:
|
활성 비교기: No Drugs & Nutrition Supplement
No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & daily nutritional supplement given to the mother. Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment. |
High energy, nutrient-dense, micronutrient fortified nutritional supplement.
Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation.
Vitamin A is excluded.
다른 이름들:
|
간섭 없음: No Drugs & No Nutrition Supplement
No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & no nutritional supplement given to the mother. Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Postpartum weight loss between delivery and 28 weeks
기간: between delivery and 28 weeks
|
between delivery and 28 weeks
|
Infant HIV status at 28 weeks. (Infants found to have HIV at birth or 2 weeks after delivery will have been disenrolled.)
기간: birth to 28 weeks
|
birth to 28 weeks
|
Exclusive breastfeeding and breastfeeding cessation by 28 weeks
기간: birth to 28 weeks
|
birth to 28 weeks
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Duration of exclusive breastfeeding
기간: birth to 28 weeks
|
birth to 28 weeks
|
Infant HIV status through 48 weeks
기간: birth to 48 weeks
|
birth to 48 weeks
|
Maternal adherence to ARV, maternal CD4 count, and clinical assessment of opportunistic infection status through 48 weeks
기간: delivery to 48 weeks
|
delivery to 48 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Peter Kazembe, MB ChB, Kamuzu Central Hospital
- 연구 의자: Charles van der Horst, MD, University of North Carolina, Chapel Hill
- 수석 연구원: Denise J Jamieson, MD, MPH, CDC, Atlanta, GA
간행물 및 유용한 링크
일반 간행물
- Flax VL, Adair LS, Allen LH, Shahab-Ferdows S, Hampel D, Chasela CS, Tegha G, Daza EJ, Corbett A, Davis NL, Kamwendo D, Kourtis AP, van der Horst CM, Jamieson DJ, Bentley ME; BAN Study Team. Plasma Micronutrient Concentrations Are Altered by Antiretroviral Therapy and Lipid-Based Nutrient Supplements in Lactating HIV-Infected Malawian Women. J Nutr. 2015 Aug;145(8):1950-7. doi: 10.3945/jn.115.212290. Epub 2015 Jul 8.
- Widen EM, Bentley ME, Chasela CS, Kayira D, Flax VL, Kourtis AP, Ellington SR, Kacheche Z, Tegha G, Jamieson DJ, van der Horst CM, Allen LH, Shahab-Ferdows S, Adair LS; BAN Study Team. Antiretroviral Treatment Is Associated With Iron Deficiency in HIV-Infected Malawian Women That Is Mitigated With Supplementation, but Is Not Associated With Infant Iron Deficiency During 24 Weeks of Exclusive Breastfeeding. J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):319-28. doi: 10.1097/QAI.0000000000000588. Erratum In: J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):e184.
- Flax VL, Bentley ME, Combs GF Jr, Chasela CS, Kayira D, Tegha G, Kamwendo D, Daza EJ, Fokar A, Kourtis AP, Jamieson DJ, van der Horst CM, Adair LS. Plasma and breast-milk selenium in HIV-infected Malawian mothers are positively associated with infant selenium status but are not associated with maternal supplementation: results of the Breastfeeding, Antiretrovirals, and Nutrition study. Am J Clin Nutr. 2014 Apr;99(4):950-6. doi: 10.3945/ajcn.113.073833. Epub 2014 Feb 5.
- Widen EM, Bentley ME, Kayira D, Chasela CS, Daza EJ, Kacheche ZK, Tegha G, Jamieson DJ, Kourtis AP, van der Horst CM, Allen LH, Shahab-Ferdows S, Adair LS; BAN Study Team. Changes in soluble transferrin receptor and hemoglobin concentrations in Malawian mothers are associated with those values in their exclusively breastfed, HIV-exposed infants. J Nutr. 2014 Mar;144(3):367-74. doi: 10.3945/jn.113.177915. Epub 2013 Dec 31.
- Widen EM, Bentley ME, Kayira D, Chasela CS, Jamieson DJ, Tembo M, Soko A, Kourtis AP, Flax VL, Ellington SR, van der Horst CM, Adair LS; BAN Study team. Maternal weight loss during exclusive breastfeeding is associated with reduced weight and length gain in daughters of HIV-infected Malawian women. J Nutr. 2013 Jul;143(7):1168-75. doi: 10.3945/jn.112.171751. Epub 2013 May 22.
- Flax VL, Bentley ME, Chasela CS, Kayira D, Hudgens MG, Kacheche KZ, Chavula C, Kourtis AP, Jamieson DJ, van der Horst CM, Adair LS. Lipid-based nutrient supplements are feasible as a breastmilk replacement for HIV-exposed infants from 24 to 48 weeks of age. J Nutr. 2013 May;143(5):701-7. doi: 10.3945/jn.112.168245. Epub 2013 Mar 6.
- Flax VL, Bentley ME, Chasela CS, Kayira D, Hudgens MG, Knight RJ, Soko A, Jamieson DJ, van der Horst CM, Adair LS. Use of lipid-based nutrient supplements by HIV-infected Malawian women during lactation has no effect on infant growth from 0 to 24 weeks. J Nutr. 2012 Jul;142(7):1350-6. doi: 10.3945/jn.111.155598. Epub 2012 May 30.
- Jamieson DJ, Chasela CS, Hudgens MG, King CC, Kourtis AP, Kayira D, Hosseinipour MC, Kamwendo DD, Ellington SR, Wiener JB, Fiscus SA, Tegha G, Mofolo IA, Sichali DS, Adair LS, Knight RJ, Martinson F, Kacheche Z, Soko A, Hoffman I, van der Horst C; BAN study team. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet. 2012 Jun 30;379(9835):2449-2458. doi: 10.1016/S0140-6736(12)60321-3. Epub 2012 Apr 26.
- Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, Martinson F, Tegha G, Knight RJ, Ahmed YI, Kamwendo DD, Hoffman IF, Ellington SR, Kacheche Z, Soko A, Wiener JB, Fiscus SA, Kazembe P, Mofolo IA, Chigwenembe M, Sichali DS, van der Horst CM; BAN Study Group. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010 Jun 17;362(24):2271-81. doi: 10.1056/NEJMoa0911486.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- RNA 바이러스 감염
- 바이러스 질환
- 혈액 매개 감염
- 전염병
- 성병, 바이러스성
- 성병
- 렌티바이러스 감염
- 레트로바이러스과 감염
- 면역 결핍 증후군
- 면역계 질환
- 느린 바이러스 질환
- HIV 감염
- 감염
- 후천성면역결핍증후군
- 약리작용의 분자기전
- 항감염제
- 항바이러스제
- 역전사 효소 억제제
- 핵산 합성 억제제
- 효소 억제제
- 항HIV제
- 항레트로바이러스제
- 항대사물질
- 프로테아제 억제제
- 시토크롬 P-450 CYP3A 억제제
- 시토크롬 P-450 효소 억제제
- 시토크롬 P-450 효소 유도제
- 시토크롬 P-450 CYP3A 유도제
- HIV 프로테아제 억제제
- 바이러스성 프로테아제 억제제
- 네비라핀
- 리토나비어
- 로피나비르
- 라미부딘
- 지도부딘
기타 연구 ID 번호
- CDC-NCCDPHP-3946
- U48CCU409660 (기타 보조금/기금 번호: U.S. Centers for Disease Control and Prevention)
- PA 04003 SIP 26-04 (기타 보조금/기금 번호: U.S. Centers for Disease Control and Prevention)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
HIV 감염에 대한 임상 시험
-
Hospital Clinic of Barcelona완전한
-
CDC FoundationGilead Sciences알려지지 않은
-
University of WashingtonNational Institute of Mental Health (NIMH)모병
-
University of Minnesota빼는HIV 감염 | HIV/에이즈 | 에이즈 | 보조기구 | 에이즈/HIV 문제 | 에이즈와 감염미국
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS Foundation완전한파트너 HIV 테스트 | 부부 에이즈 상담 | 커플커뮤니케이션 | HIV 발병률카메룬, 도미니카 공화국, 그루지야, 인도
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério da... 그리고 다른 협력자들모집하지 않고 적극적으로HIV, 신생아 HIV 조기 진단(EID), 현장 진료 검사(PoC)모잠비크, 탄자니아
-
Allegheny Singer Research Institute (also known...모집하지 않고 적극적으로
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)완전한
-
Erasmus Medical Center모병
-
Erasmus Medical Center모집하지 않고 적극적으로
Maternal zidovudine/lamivudine/lopinavir-ritonavir에 대한 임상 시험
-
University of Colorado, DenverNational Institute of Allergy and Infectious Diseases (NIAID); University of Hawaii완전한
-
Harvard School of Public Health (HSPH)National Institute of Allergy and Infectious Diseases (NIAID)종료됨
-
Assistance Publique - Hôpitaux de Paris완전한
-
CardresearchCytel Inc.; Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA알려지지 않은코로나바이러스감염증-19 : 코로나19 | 코로나바이러스 감염 | SARS-CoV 감염 | 급성 호흡기 감염 | 바이러스 질병브라질
-
ANRS, Emerging Infectious DiseasesGilead Sciences; Janssen Pharmaceutica완전한HIV 감염 | 에이즈부키 나 파소, 카메룬, 세네갈
-
ANRS, Emerging Infectious DiseasesUniversity of Bordeaux; PACCI Program알려지지 않은코로나바이러스감염증-19 : 코로나19 | 중증급성호흡기증후군 코로나바이러스 2 | COVID-19 약물 치료코트디부아르
-
Obafemi Awolowo UniversityLondon School of Hygiene and Tropical Medicine; University of California, San Diego; University... 그리고 다른 협력자들완전한